Results 41 to 44 of about 44 (44)

An antisense oligonucleotide targeting the heat‐shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis

British Journal of Pharmacology, Volume 182, Issue 12, Page 2713-2729, June 2025.
Background and Purpose Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by fibroblast activation and abnormal accumulation of extracellular matrix in the lungs. We previously demonstrated the importance of the heat shock protein αB‐crystallin (HSPB5) in TGF‐β1 profibrotic signalling, which suggests that HSPB5 could be a new ...
Pierre‐Marie Boutanquoi, Lenny Pommerolle, Lucile Dondaine, Julie Tanguy, Pierre‐Simon Bellaye, Léo Biziorek, Marine Gautier‐Isola, Bernard Mari, Denis Masnikov, Palma Rocchi, Pascal Finetti, Patricia Korczak, Brune Vialet, Philippe Barthelemy, Carmen Garrido, Philippe Bonniaud, Olivier Burgy, Françoise Goirand   +17 more
wiley   +1 more source

STAT3 Facilitates Super Enhancer Formation to Promote Fibroblast‐To‐Myofibroblast Differentiation by the Analysis of ATAC‐Seq, RNA‐Seq and ChIP‐Seq

Journal of Cellular and Molecular Medicine, Volume 29, Issue 11, June 2025.
ABSTRACT A cellular characteristic of IPF is the transformation of fibrosis into myofibroblasts. This study identifies several transcription factors—STAT3, FOXP1, JUNB, ATF3, FosL2, BATF, Fra2 and AP‐1—that play crucial roles in promoting pulmonary fibrogenesis.
Yujie Wang, Yaqin Zhao, Guohong Cao, Mengqi Jiang, Xinglong Yuan, Hongbo Li, Xiaodong Song, Jinjin Zhang, Changjun Lv, Songzi Zhang   +9 more
wiley   +1 more source

Pre‐Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients

Respirology, Volume 30, Issue 6, Page 504-514, June 2025.
ABSTRACT Background and Objective Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a poor prognosis. Antifibrotics slow the decline of pulmonary function after 12‐months, but limited studies have examined the role of circulatory biomarkers in antifibrotic treated IPF patients.
Roger M. Li, Dino B. A. Tan, Chantalia Tedja, Wendy A. Cooper, Helen E. Jo, Christopher Grainge, Ian N. Glaspole, Nicole Goh, Samantha Ellis, Peter M. A. Hopkins, Christopher Zappala, Gregory J. Keir, Paul N. Reynolds, Sally Chapman, E. Haydn Walters, Darryl Knight, Svetlana Baltic, HuiJun Chih, Tamera J. Corte, Yuben P. Moodley   +19 more
wiley   +1 more source

Characterizing the Emergence of Myeloid‐Derived Suppressor Cell Subsets in a Murine Model of Pulmonary Fibrosis

The FASEB Journal, Volume 39, Issue 10, 31 May 2025.
We hypothesize that myeloid‐derived suppressor cells (MDSCs) might be able to ameliorate pulmonary fibrosis (PF) by inhibiting local inflammation and thus its transition to fibrosis. Various parameters were assessed on days 3, 7, 14, and 21, following bleomycin challenge in mice.
Nora Vedder, Philipp Gercke, Nikoleta Lautenschlager, Tobias Brunn, Tim Lange, Jakob Schieb, Charlotte Vetter, Chiel van Geffen, Saeed Kolahian   +8 more
wiley   +1 more source